

MOLECULAR PARTNERS AG

ISIN: CH0256379097 WKN: 25637909 Asset Class: Stock

Company

2024/07/05 17:31:51



Price

6.09 CHF

Difference ▲ 4.82%(0.28)



Contact Details

MOLECULAR
PARTNERS AG

Tel: +41-44-755-77-00

--

Fax: +41-44-755-77-07

Wagistrasse 14

Web:

<http://www.molecularpartners.com>

8952 Schlieren

E-mail:

info@molecularpartners.com

Company Profile

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPin, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	192,459,000		254,752,000		164,191,000	
Common stock capital		3,635,000		3,604,000		3,229,000
Fixed assets	5,893,000		7,506,000		8,477,000	
Equity capital of a company		176,429,000		235,166,000		107,289,000
Cash and cash equivalents	186,889,000		249,144,000		132,813,000	
Accrued liabilities		5,063,000		2,552,000		6,739,000
Other assets	-		-		-	
Current liabilities		14,416,000		17,251,000		46,865,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		7,507,000		9,841,000		18,514,000
Different income		-		-		-
Other liabilities		0		3,637,000		6,925,000
Total assets	198,352,000	198,352,000	262,258,000	262,258,000	172,668,000	172,668,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	182	191	177
Equity ratio	88.95%	89.67%	62.14%
Debt-equity ratio	12.43%	11.52%	60.94%

Others

	2023	2022	2021
Tax Expense Rate	0.00%	0.00%	0.00%

MOLECULAR PARTNERS AG

ISIN: CH0256379097 WKN: 25637909 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	7,038,000	189,600,000	9,754,000
Net income	-61,984,000	117,853,000	-63,785,000
EBIT	-68,114,342	120,697,371	-65,143,456
Operating income before taxes	-61,984,000	117,853,000	-63,783,000
Cash Flow	-55,178,000	119,060,000	-90,883,000
Net interest income	4,230,000	523,000	-457,000
Research and development expenses	46,731,000	48,778,000	53,702,000
Income taxes	0	0	2,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	39,780	1,021,160	56,689

Board of Directors

Agnete Brunsvik Fredriksen	Member of the administrative board
Dominik Höchli	Member of the administrative board
Michael Vasconcelles	Member of the administrative board
Steven Holtzman	Member of the administrative board
Vito Palombella	Member of the administrative board
Sandipkumar S. Kapadia	Member of the administrative board
William Burns	Chairman of the administrative board

Members of Management Board

Patrick Amstutz	Chairman of Managing Board
Michael Tobias Stumpp	Member of Executive Committee
Alexander Zürcher	Member of Executive Committee
Philippe Legenne	Member of Executive Committee
Renate Gloggner	Member of Executive Committee